- Home
- ROIV vs EDU Comparison
ROIV vs EDU Comparison
Compare ROIV & EDU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ROIV | EDU |
|---|---|---|
| Founded | 2014 | 1993 |
| Country | United Kingdom | China |
| Employees | N/A | 84111 |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Consumer Services |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.7B | 9.4B |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | ROIV | EDU |
|---|---|---|
| Price | $28.93 | $52.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 4 |
| Target Price | $28.94 | ★ $62.80 |
| AVG Volume (30 Days) | ★ 4.3M | 805.9K |
| Earning Date | 05-28-2026 | 04-22-2026 |
| Dividend Yield | N/A | ★ 2.25% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $29,053,000.00 | N/A |
| Revenue This Year | N/A | $12.83 |
| Revenue Next Year | $744.61 | $11.16 |
| P/E Ratio | ★ N/A | $24.75 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.58 | $41.62 |
| 52 Week High | $30.33 | $64.97 |
Technical Indicators
Market Signals| Indicator | ROIV | EDU |
|---|---|---|
| Relative Strength Index (RSI) | 55.27 | 41.01 |
| Support Level | $27.00 | $50.47 |
| Resistance Level | $30.26 | $54.97 |
| Average True Range (ATR) | 0.91 | 1.51 |
| MACD | 0.01 | -0.06 |
| Stochastic Oscillator | 71.71 | 16.84 |
Price Performance
Historical ComparisonAbout ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About EDU New Oriental Education & Technology Group Inc.
New Oriental Education & Technology is a prominent private education provider in China, offering a wide array of educational services. These include overseas test preparation and consulting services, high school academic tutoring, nonacademic tutoring, and intelligent learning systems and devices. Additionally, the company holds a 57% ownership stake in East Buy, a leading player in the livestreaming e-commerce market.